- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02978625
Talimogene Laherparepvec ja Nivolumab hoidettaessa potilaita, joilla on refraktaarisia lymfoomia tai edenneitä tai refraktaarisia ei-melanooma-ihosyöpää
Vaiheen II tutkimus Talimogene Laherparepvecistä, jota seurasi Talimogene Laherparepvec + nivolumabi tulenkestävissä T-soluissa ja NK-solulymfoomissa, ihon levyepiteelisyövässä, Merkel-solukarsinoomassa ja muissa harvinaisissa ihokasvaimissa
This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.
Tutkimuksen yleiskatsaus
Tila
Ehdot
- Sezaryn oireyhtymä
- Tulenkestävä T-soluinen non-Hodgkin-lymfooma
- Merkelin solusyöpä
- Anaplastinen suurisoluinen lymfooma, ALK-positiivinen
- Extramammary Pagetin tauti
- Toistuva T-solujen non-Hodgkin-lymfooma
- Toistuva kypsä T-solu ja NK-soluinen non-Hodgkin-lymfooma
- Tulenkestävä kypsä T-solu ja NK-soluinen non-Hodgkin-lymfooma
- Tulenkestävä Mycosis Fungoides
- Tulenkestävä anaplastinen suurisoluinen lymfooma
- Epäsuoran levyepiteelisyöpä
- Ihon okasolusyöpä
- Signet-rengassolujen adenokarsinooma
- Tulenkestävä primaarinen ihon T-soluinen non-Hodgkin-lymfooma
- Anaplastinen suurisoluinen lymfooma, ALK-negatiivinen
- Apokriininen karsinooma
- Digitaalinen papillaarinen adenokarsinooma
- Endokriininen musiinia tuottava hikirauhassyöpä
- Hidradenokarsinooma
- Pahanlaatuinen hikirauhaskasvain
- Mikrokystinen adneksaalinen karsinooma
- NK-solulymfooma, luokittelematon
- Papillaarinen adenokarsinooma
- Porokarsinooma
- Primaarinen ihon limakalvosyöpä
- Tulenkestävä Merkel-solusyöpä
- Tulenkestävä ihon okasolusyöpä
- Ihon tyvisolusyöpä
- Ihon basosquamous solusyöpä
- Squamoid Eccrine Ductal Carcinoma
- Tuntemattoman primaarisen okasolusyöpä
- Hikirauhassyöpä
- Trichilemmal karsinooma
- Sylindromasta johtuva karsinooma
- Spiradenoomasta johtuva karsinooma
- Silmänulkoinen talisyöpä
- Ihon adenoidinen kystinen karsinooma
- Ihon adnexaalinen karsinooma
- Ihon keratoakantooma
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVE:
I. To determine the frequency of patients responding (response rate) to talimogene laherparepvec monotherapy.
SECONDARY OBJECTIVES:
I. To determine the local response rate to talimogene laherparepvec in injected tumors.
II. To determine the response rate to talimogene laherparepvec + nivolumab (NIVO).
III. To identify potential pre-treatment and on-treatment correlative biomarkers of local and systemic immune response.
OUTLINE:
Patients receive talimogene laherparepvec intratumorally (IT) and nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan or positron emission tomography (PET)/CT scan on study. Patients also undergo blood sample collection and biopsies on study.
After completion of study treatment, patients are followed up every 12 weeks for 3 years.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
Los Angeles, California, Yhdysvallat, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Yhdysvallat, 90033
- Los Angeles General Medical Center
-
Orange, California, Yhdysvallat, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Pasadena, California, Yhdysvallat, 91105
- Keck Medical Center of USC Pasadena
-
Sacramento, California, Yhdysvallat, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- UCHealth University of Colorado Hospital
-
-
Florida
-
Aventura, Florida, Yhdysvallat, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Yhdysvallat, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Yhdysvallat, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Yhdysvallat, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Yhdysvallat, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Yhdysvallat, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Northwestern University
-
-
Kansas
-
Fairway, Kansas, Yhdysvallat, 66205
- University of Kansas Clinical Research Center
-
Overland Park, Kansas, Yhdysvallat, 66210
- University of Kansas Cancer Center-Overland Park
-
Overland Park, Kansas, Yhdysvallat, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood, Kansas, Yhdysvallat, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Yhdysvallat, 02114
- Massachusetts General Hospital Cancer Center
-
-
Missouri
-
City of Saint Peters, Missouri, Yhdysvallat, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Yhdysvallat, 63141
- Siteman Cancer Center at West County Hospital
-
Kansas City, Missouri, Yhdysvallat, 64154
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, Yhdysvallat, 64064
- University of Kansas Cancer Center - Lee's Summit
-
North Kansas City, Missouri, Yhdysvallat, 64116
- University of Kansas Cancer Center at North Kansas City Hospital
-
St Louis, Missouri, Yhdysvallat, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Yhdysvallat, 63129
- Siteman Cancer Center-South County
-
-
Nebraska
-
Omaha, Nebraska, Yhdysvallat, 68198
- University of Nebraska Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Yhdysvallat, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
New Brunswick, New Jersey, Yhdysvallat, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Buffalo, New York, Yhdysvallat, 14263
- Roswell Park Cancer Institute
-
New York, New York, Yhdysvallat, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
North Carolina
-
Chapel Hill, North Carolina, Yhdysvallat, 27599
- UNC Lineberger Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15232
- UPMC Hillman Cancer Center
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Yhdysvallat, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Patients must have histologic or cytologic diagnosis of non-melanoma skin cancer (NMSC) or lymphomas other than B-cell lymphomas; as both of those terms are categories rather than specific diagnoses, specific guidance on eligible tumor types is provided below
-
PART I (before February 2020 amendment): Included tumor types
-
T cell and NK cell lymphomas, including, but not limited to: cutaneous T-cell lymphomas (CTCL), mycosis fungoides (MF), Sezary syndrome (SS), peripheral T-cell lymphoma (PTCL), ALK-positive and ALK-negative anaplastic large cell lymphoma (ALCL), and NK-cell lymphomas
-
Merkel cell carcinoma
-
Squamous cell carcinoma of the skin, including keratoacanthomas, vulvar squamous carcinoma, and mixed histology tumors, such as basosquamous carcinoma, and squamous cell carcinoma of unknown primary consistent with skin origin
-
Other non-melanoma skin cancers
- Basal cell carcinoma
- Malignant sweat gland tumors, including porocarcinoma, hidradenocarcinoma, spiradenocarcinoma, cylindrocarcinoma, microcystic adnexal carcinoma and related entities, squamoid eccrine ductal carcinoma, cutaneous adenoid cystic carcinoma, digital papillary adenocarcinoma, primary cutaneous mucinous carcinoma, endocrine mucin-producing sweat gland carcinoma, primary cutaneous signet ring cell carcinoma, cutaneous apocrine gland carcinoma, and extraocular sebaceous carcinoma
- Adnexal carcinoma
- Trichilemmal carcinoma
- Extramammary Paget's disease
- Any other rare tumor of the skin with approval of principle investigator (PI)
-
-
PART II (after February 2020 amendment):
- The Merkel cell carcinoma (MCC)-2 cohort will include patients with MCC
- The squamous cell carcinoma (SCC)-2 cohort will include patients with SCC
-
PART I (before February 2020 amendment): Patients with T cell and natural killer (NK) cell lymphomas must be refractory to, be intolerant of, have relapsed following, or have refused all standard life-prolonging therapies
-
PART I (before February 2020 amendment): Patients with non-melanoma skin cancers (NMSC) must have advanced or refractory tumors
- Advanced/unresectable is defined by at least 1 of the following criteria: tumors 2 cm or more, tumors considered unresectable, tumors invading deep tissues such as muscle, cartilage or bone, tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes and/or distant sites
- Refractory is defined by persistent or recurrent tumor despite prior therapy consisting of at least 1 of the following: surgery, radiation therapy, intralesional therapy, topical therapy, or systemic therapy
-
PART I (before February 2020 amendment): Subjects must have at least 1 cutaneous, subcutaneous, or nodal lesion that is suitable for intralesional injection, with or without the use of ultrasound; lesions in mucosal surfaces (periocular, nasal, etc) are not eligible for injection because the area cannot be properly contained with an occlusive dressing
-
PART I (before February 2020 amendment): Subjects must have radiographically or clinically measurable disease, defined as at least one lesion that is >= 10 mm in diameter in at least 1 dimension, or an aggregate of lesions that measures >= 10 mm in diameter in at least 1 dimension
-
PART I (before February 2020 amendment): Subjects must be able and willing to undergo serial biopsies of injected lesion(s) and, when applicable and clinically feasible, non-injected lesions
-
PART I (before February 2020 amendment): Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
PART I (before February 2020 amendment): Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
-
PART I (before February 2020 amendment): Hemoglobin >= 9 g/dL without transfusion in the preceding 7 days
-
PART I (before February 2020 amendment): Platelets >= 75 x 10^9/L
-
PART I (before February 2020 amendment): Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (patients with Gilbert's syndrome with a total bilirubin < 3.0 mg/dL)
-
PART I (before February 2020 amendment): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
-
PART I (before February 2020 amendment): Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min
-
PART I (before February 2020 amendment): Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x institutional ULN, unless the subject is on anticoagulant therapy; (if the subject is receiving anticoagulant therapy, PT, and activated PTT [aPTT] must be within therapeutic range of intended use of anticoagulants)
-
PART I (before February 2020 amendment): Talimogene laherparepvec, nivolumab and other therapeutic agents used in this trial may cause fetal harm when administered to a pregnant woman; women of child-bearing potential (WOCBP) and must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence from heterosexual intercourse) prior to study entry, during the study participation, and for 7 months after the last dose of the drug; WOCBP must have a negative serum pregnancy test within 14 days prior to randomization; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men must agree to use adequate contraception prior to study entry, during the study participation and for 7 months after the last dose of the drug
-
PART I (before February 2020 amendment): Ability to understand and the willingness to sign a written informed consent document
-
PART II (after February 2020 amendment): Subjects in expansion cohorts MCC-2 and SCC-2 must have a diagnosis of MCC or SCC, respectively
-
PART II (after February 2020 amendment): Subjects must have refractory disease, defined as evidence of progressive disease despite prior therapy with a PD-1 or PD-L1 blocking antibody (avelumab, pembrolizumab, nivolumab, cemiplimab, etc.); progression must have occurred during PD-1 or PD-L1 directed therapy or within 6 months of the last dose of PD-1 or PD-L1 directed therapy
-
PART II (after February 2020 amendment): Subjects must have at least 1 cutaneous, subcutaneous, or nodal lesion that is suitable for intralesional injection, with or without the use of ultrasound; lesions in mucosal surfaces (periocular, nasal, etc) are not eligible for injection because the area cannot be properly contained with an occlusive dressing
-
PART II (after February 2020 amendment): Subjects must have radiographically or clinically measurable disease, defined as at least one lesion that is >= 10 mm in diameter in at least 1 dimension, or an aggregate of lesions that measures >= 10 mm in diameter in at least 1 dimension
-
PART II (after February 2020 amendment): Subjects must be able and willing to undergo serial biopsies of injected lesion(s) and, when applicable and clinically feasible, non-injected lesions
-
PART II (after February 2020 amendment): ECOG performance status =< 2 (Karnofsky >= 60%)
-
PART II (after February 2020 amendment): Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
-
PART II (after February 2020 amendment): Hemoglobin >= 9 g/dL without transfusion in the preceding 7 days
-
PART II: P (after February 2020 amendment): Platelets >= 75 x 10^9/L
-
PART II (after February 2020 amendment): Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (Patients with Gilbert's Syndrome with a total bilirubin < 3.0 mg/dL.)
-
PART II (after February 2020 amendment): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
-
PART II (after February 2020 amendment): Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min
-
PART II (after February 2020 amendment): Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x institutional ULN, unless the subject is on anticoagulant therapy; (if the subject is receiving anticoagulant therapy, PT, and aPTT must be within therapeutic range of intended use of anticoagulants)
-
PART II (after February 2020 amendment): Talimogene laherparepvec, nivolumab and other therapeutic agents used in this trial may cause fetal harm when administered to a pregnant woman; women of child-bearing potential (WOCBP) and must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence from heterosexual intercourse) prior to study entry, during the study participation, and for 7 months after the last dose of the drug; WOCBP must have a negative serum pregnancy test within 14 days prior to randomization; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men must agree to use adequate contraception prior to study entry, during the study participation and for 7 months after the last dose of the drug
-
PART II (after February 2020 amendment): Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Excluded tumor types
- Melanoma
- Bone sarcomas
- Soft tissue sarcomas, including angiosarcoma, primary cutaneous leiomyosarcoma, dermatofibrosarcoma protuberans
- Leukemias
- Myeloid sarcoma, leukemia cutis, and chloroma
- Hodgkin's lymphoma
- B cell lymphoma
-
Patients who have had systemic therapy or radiotherapy within 3 weeks prior to the first dose of study therapy
-
Untreated central nervous system (CNS) involvement; patients with known brain metastases are eligible if they have been treated and are stable in the view of the treating investigator
-
Previous treatment with talimogene laherparepvec or other herpes virus based therapy; (prior therapy with checkpoint inhibitors and/or other immunotherapy is allowed)
-
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1 excepting alopecia, peripheral sensory neuropathy, and stable endocrine insufficiencies such as thyroid and adrenal insufficiency)
-
Second primary malignancy, only if it would affect the safety of the treatment or the subject's ability to complete study-related procedures
-
History or evidence of active autoimmune disease (e.g., pneumonitis, glomerulonephritis, vasculitis, or other); or history of active autoimmune disease that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases) within 2 months of enrollment; (replacement therapy [e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency] is not considered a form of systemic treatment for autoimmune disease)
-
Evidence of clinically significant immunosuppression such as the following:
- Primary immunodeficiency state such as severe combined immunodeficiency disease
- Receiving systemic immunosuppressive therapy including prednisone > 10 mg per day (or equivalent), tacrolimus, everolimus, sirolimus, mycophenolate mofetil, etanercept, infliximab, etc.
- Recipients of solid organ, bone marrow, or stem cell transplants; auto transplant recipients are allowed
- Notes: Oral steroid doses =< 10 mg/day of prednisone (or equivalent) are not considered immunosuppressive and are permitted; inhaled and intraarticular corticosteroids are permitted
-
Active herpetic skin lesions or prior complications of herpetic infection (e.g., herpetic keratitis or encephalitis)
-
Viral infections requiring intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use
-
Other viral infections:
- Known to have acute or chronic active hepatitis B or hepatitis C infection
- Known to have human immunodeficiency virus (HIV) infection
- Prior therapy with viral-based tumor vaccine
- Received live vaccine within 28 days prior to enrollment
-
Subject who is unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for human herpesvirus 1 (HSV-1) induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or children under the age of 1 year, during talimogene laherparepvec treatment and through 30 days after the last dose of talimogene laherparepvec
-
Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 7 months after the last dose of treatment; female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 7 months after the last dose of treatment; sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec
-
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components or nivolumab, or history of severe hypersensitivity reaction to any monoclonal antibody
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Treatment (talimogene laherparepvec, nivolumab)
Patients receive talimogene laherparepvec IT and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo, CT scan or PET/CT on study. Patients also undergo blood sample collection and biopsies on study. |
Correlative studies Undergo blood sample collection
Muut nimet:
Undergo CT
Muut nimet:
Given IV
Muut nimet:
Undergo tissue biopsy
Muut nimet:
Undergo PET/CT Given IT
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Response rate to talimogene laherparepvec alone (Part I)
Aikaikkuna: Up to 1 year
|
Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Up to 1 year
|
|
Best overall response rate to talimogene laherparepvec and nivolumab combination therapy (Part II)
Aikaikkuna: Up to 1 year
|
Will be assessed by RECIST version 1.1. |
Up to 1 year
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Parantavan leikkauksen tiheys (leikkausleesio muuttuu resekoitavaksi)
Aikaikkuna: Jopa 1 vuosi
|
Jopa 1 vuosi
|
|
|
Etenemisvapaa selviytyminen
Aikaikkuna: Hoidon aloittamisesta taudin etenemiseen tai kuolemaan sen mukaan, kumpi tapahtuu ensin, arvioituna 1 vuoden kuluttua
|
Hoidon aloittamisesta taudin etenemiseen tai kuolemaan sen mukaan, kumpi tapahtuu ensin, arvioituna 1 vuoden kuluttua
|
|
|
Etenemisvapaa selviytyminen
Aikaikkuna: Hoidon aloittamisesta taudin etenemiseen tai kuolemaan sen mukaan, kumpi tapahtuu ensin, arvioituna 2 vuoden kuluttua
|
Hoidon aloittamisesta taudin etenemiseen tai kuolemaan sen mukaan, kumpi tapahtuu ensin, arvioituna 2 vuoden kuluttua
|
|
|
Kokonaisselviytyminen
Aikaikkuna: 1 vuoden iässä
|
1 vuoden iässä
|
|
|
Kokonaisselviytyminen
Aikaikkuna: 2 vuoden iässä
|
2 vuoden iässä
|
|
|
Durable response rate
Aikaikkuna: Up to 1 year
|
Will be defined as complete response or partial response lasting >= 6 months. |
Up to 1 year
|
|
Response rate by cancer type
Aikaikkuna: Up to 1 year
|
Will be assessed by RECIST version 1.1. |
Up to 1 year
|
|
Response rate of injected lesions
Aikaikkuna: Up to 1 year
|
Will be assessed by RECIST version 1.1. |
Up to 1 year
|
|
Response rate of non-injected lesions
Aikaikkuna: Up to 1 year
|
Will be assessed by RECIST version 1.1. |
Up to 1 year
|
|
Incidence of adverse events
Aikaikkuna: Up to week 24
|
Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
Up to week 24
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in herpes simplex virus (HSV) serostatus assessed in blood specimens
Aikaikkuna: Baseline to week 6
|
Will be analyzed using descriptive statistics. A test of proportions will be performed. |
Baseline to week 6
|
|
Biomarker analysis of %PD-L1, flow cytometry for HVEM, NECTIN1/2, and IDO, tryptophan and L-kynurenine, cytokine levels, Nanostring, number of non-synonymous mutations, and % T-cell receptor (TCR) clonality
Aikaikkuna: Up to 1 year
|
Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed. |
Up to 1 year
|
|
Biomarker analysis of necrosis and Nanostring
Aikaikkuna: Up to 1 year
|
Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed. |
Up to 1 year
|
|
Biomarker analysis of herpes simplex virus (HSV) status, Merkel cell polyomavirus status, and PD-L1 status
Aikaikkuna: Up to 1 year
|
Will be analyzed using descriptive statistics. Test of proportions and logistic regression will be performed. |
Up to 1 year
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Ann (Annie) W Silk, Dana-Farber - Harvard Cancer Center LAO
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvioitu)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Geneettiset sairaudet, synnynnäiset
- Immuunijärjestelmän sairaudet
- Infektiot
- Virussairaudet
- Neoplasmat histologisen tyypin mukaan
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Adenokarsinooma
- DNA-virusinfektiot
- Ihosairaudet
- Lymfaattiset sairaudet
- Lymfoproliferatiiviset häiriöt
- Immunoproliferatiiviset häiriöt
- Lymfooma, non-Hodgkin
- Karsinooma
- Neuroektodermaaliset kasvaimet
- Neoplasmat, sukusolut ja alkiot
- Kasvaimet, hermokudos
- Lymfooma
- Neoplastiset oireyhtymät, perinnölliset
- Neuroendokriiniset kasvaimet
- Ihosairaudet, geneettiset
- Talirauhasten sairaudet
- Kasvainvirusinfektiot
- Ihon kasvaimet
- Kasvaimet, kystiset, limakalvoiset ja seroosit
- Polyomavirusinfektiot
- Neoplasmat, kanava-, lobulaar- ja medullaariset kasvaimet
- Neoplasmat, tyvisolut
- Karsinooma, neuroendokriininen
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Iho- ja sidekudostaudit
- Hemic- ja imusuutteet
- Talirauhasten kasvaimet
- Lynchin oireyhtymä II
- Kolorektaaliset kasvaimet, perinnöllinen ei-polypoosi
- Lymfooma, T-solu
- Lymfooma, suursoluinen, anaplastinen
- Karsinooma, tyvisolu
- Karsinooma, Merkelin solu
- Karsinooma, Signet-rengassolu
- Lymfooma, T-solu, iho
- Mycosis Fungoides
- Sezaryn oireyhtymä
- Adenokarsinooma, papillaarinen
- Pagetin tauti, extramammary
- Karsinooma, basosquamous
- Mikrokystinen adneksinen karsinooma
- Ekriininen porokarsinooma
- Muir-Torren oireyhtymä
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Tutkintatekniikat
- Kliiniset laboratoriotekniikat
- Diagnostiikkatekniikat ja menettelyt
- Diagnoosi
- Kirurgiset toimenpiteet, operatiivinen
- Sytologiset tekniikat
- Sytodiagnoosi
- Vasta -aineet, monoklonaalinen, humanisoitu
- Vasta -aineet, monoklonaalinen
- Vasta -aineet
- Immunoglobuliinit
- Immunoproteiinit
- Veriproteiinit
- Seerumin globuliinit
- Globuliinit
- Diagnostiikkatekniikat, kirurginen
- Nivolumabi
- Biopsia
- Näytteenkäsittely
- Talimogene Laherparepvec
Muut tutkimustunnusnumerot
- NCI-2016-01804
- UM1CA186716 (Yhdysvaltain NIH-apuraha/sopimus)
- 10057 (Muu tunniste: CTEP)
- UM1CA186709 (Yhdysvaltain NIH-apuraha/sopimus)
- NCI-2016-01804 (Rekisterin tunniste: CTRP (Clinical Trial Reporting Program))
- CINJ #091701
- 10057 (Muu tunniste: Dana-Farber - Harvard Cancer Center LAO)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .